Orchestra BioMed Holdings Inc [OBIO] stock prices are up 0.74% to $2.73 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The OBIO shares have gain 7.06% over the last week, with a monthly amount drifted -10.78%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Orchestra BioMed Holdings Inc [NASDAQ: OBIO] stock has seen the most recent analyst activity on August 20, 2025, when BTIG Research downgraded its rating to a Neutral. Previously, BTIG Research started tracking the stock with Buy rating on March 20, 2025, and set its price target to $12. On January 02, 2025, Barclays initiated with a Overweight rating and assigned a price target of $16 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $14 on August 22, 2024. B. Riley Securities initiated its recommendation with a Buy and recommended $15 as its price target on July 25, 2024. Jefferies started tracking with a Buy rating for this stock on January 19, 2024, and assigned it a price target of $14. In a note dated February 24, 2023, Piper Sandler initiated an Overweight rating and provided a target price of $15 on this stock.
The stock price of Orchestra BioMed Holdings Inc [OBIO] has been fluctuating between $2.37 and $7.04 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Orchestra BioMed Holdings Inc [NASDAQ: OBIO] shares were valued at $2.73 at the most recent close of the market. An investor can expect a potential return of 339.56% based on the average OBIO price forecast.
Analyzing the OBIO fundamentals
The Orchestra BioMed Holdings Inc [NASDAQ:OBIO] reported sales of 2.94M for trailing twelve months, representing a surge of 7.46%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -24.21%, Pretax Profit Margin comes in at -23.67%, and Net Profit Margin reading is -23.67%. To continue investigating profitability, this company’s Return on Assets is posted at -1.63, Equity is -2.89 and Total Capital is -2.77. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of6.68.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.68 points at the first support level, and at 2.62 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.79, and for the 2nd resistance point, it is at 2.84.
Ratios To Look Out For
It’s worth pointing out that Orchestra BioMed Holdings Inc [NASDAQ:OBIO]’s Current Ratio is 2.10. As well, the Quick Ratio is 2.09, while the Cash Ratio is 1.1. Considering the valuation of this stock, the price to sales ratio is 50.10, the price to book ratio is 357.80.
Transactions by insiders
Recent insider trading involved Fain Eric S, Director, that happened on Aug 25 ’25 when 5760.0 shares were purchased. Sherman Darren completed a deal on Aug 25 ’25 to buy 3000.0 shares. Meanwhile, Hochman David P bought 6000.0 shares on Aug 21 ’25.
